Immuno-Biological Laboratories Co., Ltd. (4570) AI Stock Analysis

• Market Cap: ¥4.65B
• Dividend Yield: N/A
• Average Volume (3M): 56.17K
• Price to Earnings (P/E): 18.4
• Beta (1Y): 0.90
• Revenue Growth: 18.71%
• EPS Growth: 33.40%
• Country: JP
• Employees: 57
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): 12.42
• Shares Outstanding: 9,314,590
• 10 Day Avg. Volume: 38,130
• 30 Day Avg. Volume: 56,166
• PEG Ratio: -1.09
• Price to Book (P/B): 3.51
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 143.27
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥572.00
• Price Target Upside: 16.50% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 68 Neutral
• Price Target: ¥534.00 ▲(8.76%Upside)

Immuno-Biological Laboratories displays strong financial health with significant revenue growth and efficient operational management. However, technical indicators suggest a cautious market sentiment. Valuation remains reasonable, but the lack of dividend yield may limit appeal.

Immuno-Biological Laboratories Co., Ltd. Business Overview & Revenue Model

Company Description

Immuno-Biological Laboratories Co., Ltd. (4570) is a biotechnology company specializing in the research, development, manufacturing, and distribution of diagnostic reagents and therapeutic products. The company operates in the life sciences sector, providing innovative solutions to support healthcare professionals and researchers in diagnosing and treating various medical conditions. Its core products include immunological and biochemical reagents for laboratory use, as well as pharmaceuticals aimed at improving patient care.

How the Company Makes Money

Immuno-Biological Laboratories Co., Ltd. generates revenue primarily through the sale of its diagnostic reagents and therapeutic products to healthcare providers, research institutions, and laboratories. The company’s revenue streams include product sales, contract research and development services, and potential licensing agreements. Additionally, partnerships with academic institutions and other biotech companies can contribute to its earnings by expanding its product offerings and market reach. The company's focus on innovation and quality drives customer demand and maintains its competitive edge in the biotechnology sector.

Immuno-Biological Laboratories Co., Ltd. Financial Statement Overview

Summary

Immuno-Biological Laboratories exhibits a commendable financial trajectory with consistent revenue growth, improved profitability, and sound balance sheet management. The strong equity foundation and efficient operations are notable.

Income Statement

Immuno-Biological Laboratories has demonstrated strong revenue growth over the years. The gross profit margin is robust at 64.8% for 2025, indicating efficient cost management. The net profit margin improved significantly to 25.7% in 2025, showing a turnaround from losses in previous years. Both EBIT and EBITDA margins have improved, reflecting better operational efficiency.

Balance Sheet

The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.13 in 2025, indicating prudent leverage. A high equity ratio of 82.0% suggests strong capitalization. The return on equity stands at 16.4%, reflecting improved profitability and efficient use of equity.

Cash Flow

The operating cash flow has increased significantly, supporting positive free cash flow growth. The operating cash flow to net income ratio is 0.74, indicating strong cash generation relative to profitability. The company has shown consistent improvement in cash flow management, enhancing financial flexibility.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	948.30M	969.53M	816.70M	794.62M	647.58M	602.75M
Gross Profit	630.76M	628.34M	517.29M	526.71M	376.70M	346.86M
EBITDA	235.56M	226.55M	128.11M	-332.00M	-249.50M	-309.88M
Net Income	299.11M	249.05M	186.69M	-289.73M	-258.77M	-318.83M
Balance Sheet
Total Assets	1.70B	1.85B	1.62B	1.43B	1.71B	1.84B
Cash, Cash Equivalents and Short-Term Investments	753.00M	825.73M	734.14M	614.16M	508.35M	604.19M
Total Debt	190.00M	204.23M	235.98M	234.99M	234.00M	90.00M
Total Liabilities	297.00M	331.03M	353.27M	355.72M	336.99M	208.76M
Stockholders Equity	1.40B	1.51B	1.27B	1.08B	1.37B	1.63B
Cash Flow
Free Cash Flow	0.00	123.83M	115.11M	26.46M	-93.20M	-207.60M
Operating Cash Flow	0.00	183.50M	133.78M	26.46M	-93.20M	-194.15M
Investing Cash Flow	0.00	-53.66M	-24.50M	30.04M	-155.63M	-17.23M
Financing Cash Flow	0.00	-31.75M	991.00K	991.00K	144.00M	-216.00M

Immuno-Biological Laboratories Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 491.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4570, the sentiment is Negative. The current price of 491 is below the 20-day moving average (MA) of 500.10, below the 50-day MA of 500.22, and above the 200-day MA of 482.99, indicating a neutral trend. The MACD of -3.27 indicates Positive momentum. The RSI at 43.98 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4570.

Immuno-Biological Laboratories Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4570	68 Neutral	¥4.65B	18.36		―	18.71%	33.40%
4594	59 Neutral	¥8.35B	―		―	1473.61%	22.80%
4884	54 Neutral	¥5.85B	―		―	12.66%	24.73%
Sector *	52 Neutral	$7.53B	0.20	-61.87%	2.28%	16.72%	1.10%
4881	38 Underperform	¥4.30B	―		―	1056.04%	21.63%
4591	37 Underperform	¥5.09B	―		―	-96.64%	8.92%
4598	28 Underperform	¥7.99B	―		―	―	-11.46%